Protalix BioTherapeutics, Inc. (AMEX:PLX) biopharmaceutical firm will be discussing 2Q20 financial results with the investment community.on 10th August 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.protalix.com
Earnings Expectation
Protalix BioTherapeutics, Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, PLX is expected to report 2Q20 loss of $ 0.2 per share from revenue of $ 10.87 million.
For the full year, analysts anticipate top line of $ 53.79 million, while looking forward to loss of $ 0.54 per share bottom line.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis.
